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CORRESPONDENCE
Clusters of Differentiation 24 Polymorphism and Hepatocellular Carcinoma
To the Editor:
We read with great interest the recent report by Li et al.1 ana-
lyzing the correlation between the clusters of differentiation 24
(CD24) polymorphism and risk of chronic hepatitis B virus
(HBV) infection. In their study, the CD24 P170 T allele (thymi-
dine at position 170) was correlated with a strong, statistically sig-
niﬁcant increased risk of developing chronic HBV infection. They
also showed that CD24 polymorphism may associate with develop-
ment of hepatocellular carcinoma (HCC). Chronic HBV infection
is one of the most important risk factors for HCC. Many patients
with chronic HBV infection are more prone to develop liver cir-
rhosis and HCC when the infection is rampant. In view of these
theories, genetic variants underlying chronic HBV infection should
be related to HCC susceptibility.
Results of a genome-wide association show the overlapping rela-
tion of the Corticotropin-releasing hormone receptor 2 (CRHR2)
gene with HCC mediated largely through its association with
HBV infection.2 To analyze if CD24 polymorphisms are associated
with host susceptibility to HCC, we described a case–control study
of 235 cases with HCC and 268 healthy controls in a southeast
Chinese population. All patients presented clear histopathological
conﬁrmation of HCC. Patients who had preoperative chemother-
apy or preoperative chemoradiotherapy were excluded. Population
controls were selected from a pool of cancer-free subjects living in
the same region as the cases. The control subjects were frequency-
matched to the cases on sex and age. The T/T homozygote in
CD24 P170 was correlated with a strong, statistically signiﬁcant
increased risk of developing HCC (adjusted odds ratio ¼ 2.96,
95% conﬁdence interval ¼ 1.54-5.79; Table 1). Hence, we pro-
posed that genes underlying a susceptibility to chronic HBV infec-
tion may also be relevant to HCC. This result is analogous to the
overlapping relation of gene polymorphism with lung cancer that
is mediated largely through its association with chronic obstructive
pulmonary disease.3
HCC is one of the most common malignant neoplasms in
the world. HBV, hepatitis C virus, excessive alcohol intake, and
exposure to aﬂatoxin B1 are major risk factors for the development
of HCC. Approximately 80% of HCC incidence worldwide is
etiologically associated with HBV. In view of these facts, HCC is
the outcome of chronic inﬂammation. Genes regulated in local
inﬂammation may be linked with HCC through inﬂammatory or
immune-modulating pathways. Liver inﬂammation induced by
hepatitis B is produced by the cellular immune response against vi-
ral antigens present in infected hepatocytes. In this local microen-
vironment, preneoplastic transformation of hepatocytes is believed
to happen. This therefore shows that the CD24 P170 T/T geno-
type increases the risk of HCC. Genetic factors underlying HBV
could be related to HCC risk. Future genome-wide association
studies may consider this overlap phenomenon.
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Table 1. Association Between CD24 P170 Genotype and Risk of HCC
Genotype Control n (%) Case n (%) Crude OR (95% CI) P *Adjusted OR (95% CI) P
CC 136 (50.7) 109 (46.4) 1.0 1.0
CT 117 (43.7) 90 (38.3) 0.96 (0.66-1.39) 0.829 0.95 (0.65-1.38) 0.788
TT 15 (5.6) 36 (15.3) 2.99 (1.56-5.75) 0.001 2.96 (1.54-5.79) 0.001
CI, conﬁdence interval; OR, odds ratio.
*OR were adjusted by sex.
Reply:
We read with great interest the letter by Sheng and Shui. The
data presented are consistent with our initial observation that the
cluster of differentiation (CD)24 polymorphism associates with pro-
gression from chronic hepatitis B Virus infection to liver cirrhosis
and hepatocellular carcinoma (HCC).1 We also reported, in a trans-
genic model of HCC, that targeted mutation of the CD24 gene
reduces the size of HCC in the mice. The compelling data by Sheng
and Shui raised an import issue on the role for CD24 in HCC
pathogenesis. Although we have not observed CD24 expression in
HCC samples, recent work by Lee et al.2 suggests that CD24 is a
marker for HCC stem cells and may play an important role in
HCC stem cell function. It would be of great interest to determine
whether the function of CD24 is to regulate adaptive3 and innate
immune responses4 or HCC stem cell function2 or both.
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Idiopathic Noncirrhotic Intrahepatic Portal Hypertension Is an Ongoing Problem in India
To the Editor:
Schouten et al. describe the need for histological conﬁrma-
tion of idiopathic noncirrhotic portal hypertension and its con-
trasting incidence between the West and India.1 We prefer the
term idiopathic noncirrhotic intrahepatic portal hypertension
(NCIPH) to distinguish it from extrahepatic portal vein throm-
bosis—the most common cause of pediatric portal hypertension
at our center.2
After the report from Chandigarh in 2002,3 there is
scarce literature on the incidence of biopsy-proven NCIPH
in India. We herein report on our recent experience with
NCIPH.
From 2005 to 2007, retrospective analysis of 227 portal hy-
pertensive patients who underwent liver biopsy at our center
showed that of 62 patients labeled as having ‘‘cryptogenic cirrho-
sis,’’ 30 (48%) were diagnosed as having NCIPH after liver
biopsy.4
We prospectively studied the prevalence of NCIPH among all
new portal hypertensive patients in our unit from July 2009 to
July 2010 (after institutional ethics committee approval). NCIPH
was diagnosed as per the previously described criteria.4 The need
for liver biopsy in each patient was decided on a case-by-case basis,
based on the clinical scenario.
Of 610 consecutive new portal hypertensive patients studied,
cryptogenic cirrhosis (210 patients) was the most common cause
of portal hypertension identiﬁed after noninvasive tests. Of 44
cryptogenic cirrhosis patients who underwent liver biopsy, 17
(39%) had NCIPH and 8 had ‘‘true cryptogenic cirrhosis.’’
NCIPH and true cryptogenic cirrhosis patients were 27 (range,
14-59) and 42 (range, 25-67) years old, respectively; 10 and 4
patients, respectively, were males. Hepatic venous pressure gradi-
ent measured in 15 NCIPH and 4 true cryptogenic cirrhosis
patients was 7 (range, 1-21) and 18 (range, 10-27) mmHg,
respectively (P ¼ 0.012).
Liver biopsies were performed percutaneously in 4 NCIPH
patients and transjugularly in 13. Number of cores in percutane-
ous biopsies was 3 per patient and 3 (range, 1-6) in transjugular
biopsies; length of the largest core was 13 (range,12-15) in percu-
taneous and 12 mm (range, 6-16) in transjugular biopsies. The
number of portal tracts in liver biopsies was 10 (range, 5-20).
Liver biopsies showed no signiﬁcant ﬁbrosis (6 patients), mild
portal/periportal ﬁbrosis (10), moderate ﬁbrosis (1), mild perisi-
nusoidal ﬁbrosis (1), abnormal portal venous ectasia (6), and
mild diffuse sinusoidal dilatation (8); no patient had cirrhosis or
severe ﬁbrosis.
In summary, in 2009-2010 and 2005-2007,4 39%-48% of
patients with clinical diagnosis of cryptogenic cirrhosis who under-
went liver biopsy at our center had NCIPH.
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Reply:
We would like to thank Goel et al. for their reply to our review
of idiopathic noncirrhotic portal hypertension (INCPH).1,2
The authors studied the prevalence of INCPH among all new
portal hypertension patients from July 2009 until July 2010. Even-
tually, 17 (39%) patients were diagnosed with INCPH. The
authors described the morphological features observed in liver
specimens from these 17 INCPH patients. Interestingly, neither
2274 CORRESPONDENCE HEPATOLOGY, December 2011
the presence of nodular regenerative hyperplasia nor obliteration of
portal venules (phlebosclerosis)—both the most frequently observed
morphological features in liver specimens of Western INCPH
patients—were found.3,4 The apparent absence of these features in
Indian INCPH patients could imply differences in pathophysiolog-
ical mechanisms between patients from different continents.
As reported by Goel et al., liver biopsy is mandatory in the diag-
nosis of INCPH. Its main role is the exclusion of liver cirrhosis,
which may be very difﬁcult to discern by radiological examinations
only. In addition, the diagnosis of INCPH can be suggested or sup-
ported by the presence of morphological features such as nodular re-
generative hyperplasia, phlebosclerosis, increased number of portal
vascular channels, paraportal shunt vessels, and sinusoidal dilatation.
However, one must take into account that these features can also be
observed in patients without clinical signs of portal hypertension.
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I148M Variant of PNPLA3 Confer Increased Risk for Nonalcoholic Fatty Liver Disease
Not Only in European Population, but Also in Chinese Population
To the Editor:
We read, with great interest, the article by Sookoian et al.
reporting on when after having performed a systematic review by a
meta-analysis, they found that the I148M variant of PNPLA3 can
be used as a risk marker for predicting susceptibility and histologi-
cal severity of nonalcoholic fatty liver disease (NAFLD).1 Here, we
would like to draw attention to our similar studies between
rs738409 in PNPLA3 and NAFLD in the Chinese population and
that we found signiﬁcant associations between rs738409 and
NAFLD.
Recent genome-wide association studies revealed that the
genetic variation, rs738409 (I148M), in PNPLA3 inﬂuences
NAFLD and plasma levels of liver enzymes.2-4 However, the associ-
ation of rs738409 with the development and severity of NAFLD
in the Chinese population has not yet been reported. We tested
the association of histologic NAFLD with the I148M variant of
PNPLA3 in 112 patients of NAFLD and 120 matched controls in
our department. Our results showed that in the Chinese popula-
tion, individuals harboring the G allele of rs738409 were suscepti-
ble to NAFLD, and that rs738409 was associated with the histo-
logical ﬁbrosis stage. PNPLA3 may be involved in the progression
of ﬁbrosis in NAFLD. Our results showed that the rs738409 G
allele in PNPLA3 was signiﬁcantly associated with increased odds
of histologic NAFLD (odds ratio [OR] ¼ 3.03; 95% conﬁdence
interval [CI] ¼ 1.98-6.71). After analysis of the association
between the G allele of rs738409 in PNPLA3 and the steatosis
grade, we found that there was not an association (P > 0.05). Fur-
thermore, we also did not observe any association of this variant
with body mass index, triglyceride levels, high- and low-density lip-
oprotein levels, or diabetes (P > 0.05). Generally, our research
results are very similar to Prof. Sookoian’s previous report.
In summary, our data highlight three points. First, we show
that genetic variation at PNPLA3 confers a markedly increased risk
of increasingly severe histological features of NAFLD, not only
limited to European populations. Second, our research sample size
is small and only a single central research, and this did not allow
us to get the better results, compared with Prof. Sookoian’s report.
Third, although the genotypes of different geographic and ethnic
factors may have a signiﬁcant effect on the above results, we still
want to say that the I148M variant of PNPLA3 can be used as a
risk marker for predicting the susceptibility and histological severity
of NAFLD in the Chinese population.
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Noninvasive Assessment of Liver Fibrosis: the Clinical Context and Question are Important
To the Editor:
We read the recent article on noninvasive assessment of liver
ﬁbrosis, and we would like to make some comments.1
First, when using a noninvasive marker in a speciﬁc patient,
both the clinical context and question are important. The sensitiv-
ity, speciﬁcity, and area under the receiver operating characteristic
curve of a noninvasive test are not enough. In our recent meta-
analysis of transient elastography (TE), we incorporated pretest
probabilities as well as summary sensitivities and speciﬁcities to cal-
culate post-test probabilities and, therefore, clinically translate the
performance of such markers.2 If we assume that TE is used as a
screening tool to detect cirrhosis (pretest probability ¼ 0.5), a
measurement above the cirrhosis cut-off value would mean a 90%
probability of cirrhosis, whereas a measurement below this value
would suggest a cirrhosis risk of 16%. Obviously, by manipulating
the cut-off, either sensitivity or speciﬁcity can be increased at the
expense of the other, depending on the clinical question, but this
has not been adequately addressed, to date. For instance, if nonin-
vasive tests are to be used as population-screening tests for ﬁbrosis,
then the emphasis should be on enhancing sensitivity. In an indi-
vidual patient, if the index of suspicion for ﬁbrosis/cirrhosis is low,
one would need enhanced speciﬁcity, whereas with a high suspicion
index, an enhanced sensitivity is more useful.
Second, noninvasive markers do not provide unexpected addi-
tional or alternative diagnoses. In this speciﬁc case scenario, there
would be no information on steatosis, which is associated with
ﬁbrosis severity and treatment outcome.
Third, because the evaluation of noninvasive markers is shifting
to clinical outcomes, it is important to remember that histological
staging is descriptive and categorical and not designed as a prog-
nostic tool. Therefore, regarding clinical outcomes, noninvasive ﬁ-
brosis markers should be compared to established prognostic mod-
els. If histology is to be used a comparator for prognostic studies,
then a quantitative histological assessment, such as collagen propor-
tionate area or other prognostically validated morphometric
approach, should be used.3
Last, sensitivities and speciﬁcities of noninvasive ﬁbrosis
markers are probably overestimated, because failed measurements
are not calculated in the estimation of these parameters. This needs
to be addressed in future studies.
In conclusion, noninvasive markers should be used and inter-
preted in the speciﬁc context of individual patients, because,
clearly, one size does not ﬁt all. Regarding the patient in the case
scenario, we would advocate the performance of liver biopsy,
because noninvasive tests can only potentially diagnose, but not
exclude, cirrhosis and cannot give any other reliable information
apart from this.
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Targeting the Renin-Angiotensin System: Potential Beneﬁcial Effects of the Angiotensin II Receptor
Blockers in Patients with Nonalcoholic Steatohepatitis
To the Editor:
We read, with great interest, the article by Torres et al. about
the efﬁcacy of combination therapy with rosiglitazone and met-
formin or losartan on improving liver histology in patients with
nonalcoholic fatty liver diseases; the investigators conclude that
adjuvant therapies are ineffective.1 It is certainly a very interest-
ing study to ﬁnd out some prospect ideas about the therapeutic
potential of ‘‘combination effects’’ or ‘‘combination therapy,’’
because we are still uncertain as to whether or not disregarding
combination therapy is a good option for nonalcoholic steatohe-
patitis (NASH) patients. As discussed by the investigators, an
interesting drug to consider is telmisartan, which also acts as a
partial agonist of peroxisome proliferator-activated receptor gamma.
In fact, in addition to the observed effects on fatty liver rever-
sion, telmisartan is able to improve insulin resistance, but is less
effective than losartan in preventing plasminogen-activator inhib-
itor-1 gene expression.2 Therefore, combining both actions in
one molecule may improve some aspects of NASH, but not all of
them.
At any rate, there are other reasons to think about the impor-
tance of the blockade of the renin-angiotensin system (RAS) in the
liver of NASH patients. Perhaps, in the study of Torres et al.,
improvement in body weight was not as expected, because treat-
ment with thiazolidinediones may prevent an interesting, poorly
explored effect of angiotensin receptor blockers (ARBs) on the reg-
ulation of body weight.2 In addition, we recently observed a local
upregulation of the angiotensin I–converting enzyme in the liver of
patients with NASH, suggesting a putative role of the RAS in the
progression of liver histology.3
Finally, the investigators speculated that both environmental
and genetic inﬂuences are likely involved in the lack of universal
improvement observed in the patients enrolled in this trial. Can
we expect that all patients are equal responders to the therapy?
Certainly, we cannot. We previously showed that a gene variant
(A1166C) in the angiotensin II type 1 receptor predicts the
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therapeutic response to losartan; we found a higher response to los-
artan among AA homozygous.4 We wonder whether, before dis-
charging ARBs, we might improve our ability to select patients
who are able to respond better, tailoring the therapy, depending on
their genetic background.
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Metabolic Syndrome is Also a Risk Factor for Primary Liver Cancer in Patients Younger
than 65 Years of Age?
To the Editor:
We read with great interest the article by Welzel et al.1 The
study reported a positive association between metabolic syndrome
and hepatocellular carcinoma (HCC), but the results were re-
stricted to people aged 65 years of age. Although the incidence
of obesity and/or metabolic syndrome is showing no sign of
decline, the epidemic of hepatitis B (HBV) and C (HCV) viruses
is at its peak, thus increasing the incidence of HCC.2,3 To provide
further insights on the association of HCC and metabolic syn-
drome on the interaction with HBV/HCV infection, we report
data from an Italian case–control study on HCC. The study was
conducted between 1999 and 2002 in the province of Pordenone,
Northeastern Italy, and in Naples, Southern Italy.4 Cases comprised
185 patients aged 43-84 years (50% below age 65 years) with inci-
dent HCC, who had not yet received any cancer treatment at study
entry. The control group included 412 cancer-free patients from
the same areas as the cases.4
Metabolic syndrome was associated with a four-fold higher risk
of HCC. The association was conﬁrmed among hepatitis B surface
antigen (HBsAg)-negative and antibody to HCV (anti-HCV)-nega-
tive subjects (odds ratio [OR] ¼ 4.00; 95% conﬁdence interval
[CI] ¼ 1.30-12.27). According to the individual preexisting medi-
cal condition, only diabetes was signiﬁcantly associated with HCC
Table 1. Multiple Logistic Regression Analysis Examining the Association Between HCC and Each Preexisting Medical
Condition Contributing to Metabolic Syndrome
HCC Controls
Preexisting Medical Conditions N % N % OR (95% CI)* P Value
All study subjects 185 404
Diabetes 37 20.0 26 6.4 3.75 (1.66-8.44) 0.0001
Hypercholesterolemia 2 1.1 24 5.9 0.52 (0.08-3.39) 0.63
Hypertension 41 22.2 116 28.7 1.17 (0.63-2.17) 0.50
Obesity 114 61.6 258 63.9 1.26 (0.72-2.20) 0.42
Metabolic syndrome 10 5.4 16 4.0 4.00 (1.30-12.27) 0.015
HBsAg-negative and anti-HCV-negative 38 360
Diabetes 9 23.7 23 6.4 3.52 (1.34-9.23) 0.011
Hypercholesterolemia 1 2.6 23 6.4 0.69 (0.08-5.81) 0.73
Hypertension 16 42.1 101 28.1 2.07 (0.92-4.65) 0.078
Obesity 29 76.3 232 64.4 1.95 (0.82-4.67) 0.13
Metabolic syndrome 6 15.8 15 4.2 4.19 (1.23-14.23) 0.022
*Adjusted for center, sex, age, education, drinking status, maximum lifetime alcohol intake, smoking status, cigarettes per day, hepatitis B surface antigen
(HBsAg) and/or antibody to HCV (anti-HCV) positivity, when appropriate.
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risk (OR ¼ 3.75; 95% CI ¼ 1.66-8.44; Table 1). This result was
in agreement with a recent study.5
Our results are therefore in agreement with the study by Welzel
et al.1; in particular, our study conﬁrms that metabolic syndrome
is also a risk factor for HCC in people younger than 65 years
(50% of our study population).
Our results on metabolic syndrome, together with heavy drink-
ing (in the North) and high HCV prevalence (in the South), con-
tribute to explain the high incidence of and mortality rates from
HCC in Italy.3,6 In order to reduce the burden of liver cancer,
actions to control the recent epidemic of metabolic syndrome
should be promoted.
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Ribavirin Pharmacokinetics and Interleukin 28B Plus Cytochrome P450 27B1 Single-Nucleotide
Polymorphisms as Predictors of Response to Pegylated Interferon/Ribavirin Treatment in Patients
Infected with Hepatitis C Virus Genotype 1/4
To the Editor:
Bitetto et al. described how vitamin D serum level is comple-
mentary to the interleukin 28B (IL28B; rs12979860) polymor-
phism in predicting the achievement of sustained virological
response (SVR) in treatment-naive patients receiving standard
pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treat-
ment of genotype 1 chronic hepatitis C virus (HCV).1
It should be also noted how vitamin D serum levels may
be inﬂuenced by polymorphisms in the gene coding for a
related metabolic enzyme (cytochrome P450 27B1
[CYP27B1]).2 The association between responsiveness to therapy
for difﬁcult-to-treat HCV infections and IL28B (rs12979860
and rs8099917) single-nucleotide polymorphisms (SNPs) were
evaluated.1,3
Prior to the discovery of these new predictive factors, both dos-
age and pharmacokinetic exposure of RBV have been repeatedly
found to be associated with the therapeutic outcome of chronic
HCV hepatitis.4,5 No data are, however, yet available on the inter-
play between RBV pharmacokinetics and these newly introduced
predictive factors.
In the analysis of 91 patients with chronic genotype 1/4 HCV
hepatitis who received standard Peg-IFN/RBV treatment, we found
that further to IL28B (rs8099917) SNP (odds ratio [OR] ¼ 2.83,
95% conﬁdence interval [CI] ¼ 1.08-7.39, P ¼ 0.034) and
CYP27B1 (rs4646536) SNP (OR ¼ 3.90, 95% CI ¼ 1.37-11.14,
P ¼ 0.011), the presence of RBV concentrations >2500 ng/mL
(OR ¼ 3.08, 95% CI ¼ 1.21-7.85, P ¼ 0.019) was an independ-
ent predictor of SVR.
It is worth noting (Fig. 1) how no patients with all three unfav-
orable factors had SVR, whereas a tendency to higher rates of SVR
was seen according to the combination of favorable genetic and
RBV pharmacokinetic factors. These results reveal that rs8099917
G allele, rs4646536 C allele (related to low 25-hydroxyvitamin D3
serum concentrations), and RBV plasma concentrations (<2500
ng/mL) could predict which patients are likely to experience treat-
ment failure in this group of difﬁcult-to-treat HCV-infected
patients.
Based on these ﬁndings, we believe that in addition to these
recently characterized human genetic factors, the individual phar-
macokinetic exposure to RBV should not be neglected among the
predictors of anti-HCV treatment outcome.
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Fig. 1. Number and percentage of patients with SVR (white columns) and without SVR (black columns), stratiﬁed for each predictor factor
combinations.
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